3,4-Methylenedioxymethamphetamine

Phase 3

UUniversity Hospital, Basel, Switzerland

3,4-Methylenedioxymethamphetamine is one of 55 therapeutic programs targeting Post-Traumatic Stress Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Post-Traumatic Stress DisorderActive, not recruiting

Post-Traumatic Stress DisorderPhase 3

Active, not recruiting

Competition

Competitive Landscape

61 competitors in Post-Traumatic Stress Disorder

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

5 2

Minipress

Pfizer

Approved

4 3

Epidiolex

Jazz Pharmaceuticals

Approved

2 4

Ritalin

Novartis

Approved

1 5

Namenda

AbbVie

Approved

1 6

Marinol

Jazz Pharmaceuticals

Approved

1 7

Revia

Teva

Approved

1 8

Zoloft

VViatris Specialty LLC

Approved

7 9

Inderal

WWyeth-Lederle Vaccines

Approved

5 10

Paxil

SSebela Pharmaceuticals Development LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Post-Traumatic Stress Disorder

NCT06117306

Q1 2028

Phase 2Recruiting

Post-Traumatic Stress Disorder

NCT05790239

Q4 2028

Phase 2Recruiting

Neuropathic Pain

NCT07301632

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder2 trials

MDMA-assisted Massed Prolonged Exposure for PTSD

Active, not recruiting·HHealing Breakthrough·Phase 3·NCT06117306·20 enrolled

A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans For The Treatment of Moderate to Severe PTSD

Recruiting·SStephen Robert Marder·Phase 2·NCT05790239·40 enrolled

Neuropathic Pain1 trial

Ecstasy to Alleviate SEvere Chronic Neuropathic Pain (EASE Pain) Trial: A Randomized Controlled Pilot Trial

Recruiting·UUnity Health Toronto·Phase 2·NCT07301632·50 enrolled

Unspecified1 trial

Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06884514·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for 3,4-Methylenedioxymethamphetamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 3,4-Methylenedioxymethamphetamine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Basel, Switzerland

3,4-Methylenedioxymethamphetamine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Q4 2028

Trials by Indication[1]

Post-Traumatic Stress Disorder2 trials

Neuropathic Pain1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News